home / stock / cyad / cyad news

CYAD News and Press, Celyad SA From 08/01/22

Stock Information
Company Name: Celyad SA
Stock Symbol: CYAD
Market: NASDAQ
Menu
CYAD CYAD Quote CYAD Short CYAD News CYAD Articles CYAD Message Board
Get CYAD Alerts

News, Short Squeeze, Breakout and More Instantly...
CYAD - Celyad stock soars 35% as FDA lifts hold on colorectal cancer trial of CYAD-101/Keytruda

Celyad Oncology ( NASDAQ: CYAD ) said the the U.S. Food and Drug Administration (FDA) a lifted a clinical hold on a phase 1b trial of its CAR T cell therapy CYAD-101, after the company made changes to the eligibility criteria for the trial. In March, the FDA placed a ...
CYAD - Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial

MONT-SAINT-GUIBERT, Belgium, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the U.S. Fo...

CYAD - Celyad Oncology to Announce First Half 2022 Financial Results and Host Conference Call

MONT-SAINT-GUIBERT, Belgium, July 28, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company...

CYAD - 1Life, Tabula Rasa top healthcare gainers; LumiraDx, Verve lead losers' pack

Gainers: 1Life Healthcare ONEM +67% . Tabula Rasa HealthCare ( TRHC ) +27% . Cano Health ( CANO ) +15% . Repligen ( RGEN ) +15% . Oak Street Health ( OSH ) +10% . Losers: LumiraDx LMDX -25% . Verve Therapeuti...
CYAD - Apellis, Neuronetics top healthcare gainers; High Tide, Ultragenyx lead losers' pack

Gainers: Apellis Pharmaceuticals APLS +22% . Neuronetics STIM +17% . Nyxoah ( NYXH ) +17% . Celyad Oncology ( CYAD ) +8% . NuCana ( NCNA ) +7% . Losers: High Tide HITI -21% . Ultragenyx Pharmaceutical ( RARE ...

CYAD - Celyad: Probably Still Top-Notch In Oncology

Celyad is a seemingly neglected immuno-oncology-focused nano-cap, liked by analysts and experts abound, but somehow overlooked by the market. Four months ago, its share price took a dive following a clinical hold in a trial of CAR-T candidate CYAD-101 in combination with Keytruda. ...

CYAD - Celyad Oncology Announces Leadership Updates

MONT-SAINT-GUIBERT, Belgium, June 24, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, to...
CYAD - CIG, BTCM and CYAD among mid-day movers

Gainers: NeuroMetrix (NURO) +34%. Millicom International (TIGO) +32%. Grab Holdings (GRAB) +30%. SIGA Technologies (SIGA) +26%. Celyad Oncology (CYAD) +19%. Clene (CLNN) +19%. Applied Blockchain (APLD) +19%. Immunome (IMNM) +18%. BIT Mining (BTCM) +18%. Losers: Companhia Energetica de Minas G...

CYAD - Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference

MONT-SAINT-GUIBERT, Belgium, May 17, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, tod...

CYAD - CORRECTION - Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights

MONT-SAINT-GUIBERT, Belgium, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Celyad Oncology SA (Euronext & Nasdaq: CYAD), please note that in the First Quarter 2022 Financial Review section, the figures for cash and cash equivalents an...
Previous 10 Next 10